Diagnosis and Treatment of Hodgkin Lymphoma

作者: Peter H. Wiernik

DOI: 10.1007/978-3-319-64263-5_43

关键词:

摘要: The successful treatment of Hodgkin lymphoma is one the most impressive achievements modern medicine. Today more than 90% patients without fever, weight loss, or night sweats (B symptoms) are cured with optimal treatment, and 60–70% those B symptoms as well. Fortunately, do not have at presentation. These cure rates been achieved problems. Long-term complications interrupted well-being a sizeable fraction survivors, relapses—even late relapses—are still problem. Current clinical research focused on noninvasive staging disease, reducing short- long-term early diagnosis serious such cardiac disease second malignancies. For first time in decades new drugs major activity against identified their role currently being defined.

参考文章(413)
David Sibon, Franck Morschhauser, Matthieu Resche-Rigon, David Ghez, Jehan Dupuis, Ambroise Marçais, Bénédicte Deau-Fischer, Reda Bouabdallah, Catherine Sebban, Gilles Salles, Pauline Brice, Single or tandem autologous stem-cell transplantation for first-relapsed or refractory Hodgkin lymphoma: 10-year follow-up of the prospective H96 trial by the LYSA/SFGM-TC study group. Haematologica. ,vol. 101, pp. 474- 481 ,(2016) , 10.3324/HAEMATOL.2015.136408
G P Biti, G Cimino, C Cartoni, S M Magrini, A P Anselmo, R M Enrici, G P Bellesi, A Bosi, G Papa, D Giannarelli, Extended-field radiotherapy is superior to MOPP chemotherapy for the treatment of pathologic stage I-IIA Hodgkin's disease: eight-year update of an Italian prospective randomized study. Journal of Clinical Oncology. ,vol. 10, pp. 378- 382 ,(1992) , 10.1200/JCO.1992.10.3.378
S L Wolden, K R Lamborn, S F Cleary, D J Tate, S S Donaldson, Second cancers following pediatric Hodgkin's disease. Journal of Clinical Oncology. ,vol. 16, pp. 536- 544 ,(1998) , 10.1200/JCO.1998.16.2.536
Paloma Martín, Isabel Krsnik, Belen Navarro, Mariano Provencio, Juan F. García, Carmen Bellas, Carlos Vilches, Natalia Gomez-Lozano, HLA Allele E*01:01 Is Associated with a Reduced Risk of EBV-Related Classical Hodgkin Lymphoma Independently of HLA-A*01/*02 PLOS ONE. ,vol. 10, pp. e0135512- ,(2015) , 10.1371/JOURNAL.PONE.0135512
L. Strobbe, L. L. F. G. Valke, I. J. Diets, M. van den Brand, K. Aben, J. M. M. Raemaekers, K. M. Hebeda, J. H. J. M. van Krieken, A 20-year population-based study on the epidemiology, clinical features, treatment, and outcome of nodular lymphocyte predominant Hodgkin lymphoma. Annals of Hematology. ,vol. 95, pp. 417- 423 ,(2016) , 10.1007/S00277-015-2578-6
A Santoro, G Bonadonna, P Valagussa, R Zucali, S Viviani, F Villani, A M Pagnoni, V Bonfante, R Musumeci, F Crippa, Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy. Journal of Clinical Oncology. ,vol. 5, pp. 27- 37 ,(1987) , 10.1200/JCO.1987.5.1.27
Michael H Covinsky, Rongzhen Zhang, Adan Rios, Nghia D Nguyen, Binara Assylbekova, Robert E Brown, Andr�s E. Quesada, Christine E. Jabcuga, Expression of Sirt1 and FoxP3 in classical Hodgkin lymphoma and tumor infiltrating lymphocytes: Implications for immune dysregulation, prognosis and potential therapeutic targeting. International Journal of Clinical and Experimental Pathology. ,vol. 8, pp. 13241- 13248 ,(2015)
A Rashidi, M Ebadi, A F Cashen, Allogeneic hematopoietic stem cell transplantation in Hodgkin lymphoma: a systematic review and meta-analysis. Bone Marrow Transplantation. ,vol. 51, pp. 521- 528 ,(2016) , 10.1038/BMT.2015.332
Francesco Zallio, Stefania Tamiazzo, Chiara Monagheddu, Francesco Merli, Fiorella Ilariucci, Caterina Stelitano, Anna Marina Liberati, Donato Mannina, Umberto Vitolo, Emanuele Angelucci, Delia Rota Scalabrini, Daniele Vallisa, Monica Bellei, Alessia Bari, Giovannino Ciccone, Flavia Salvi, Alessandro Levis, Reduced intensity VEPEMB regimen compared with standard ABVD in elderly Hodgkin lymphoma patients: results from a randomized trial on behalf of the Fondazione Italiana Linfomi (FIL). British Journal of Haematology. ,vol. 172, pp. 879- 888 ,(2016) , 10.1111/BJH.13904